Belinostat (PXD101)

For research use only.

Catalog No.S1085 Synonyms: NSC726630, PX-105684

71 publications

Belinostat (PXD101) Chemical Structure

CAS No. 414864-00-9

Belinostat (PXD101, NSC726630, PX-105684) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1317.13 In stock
RMB 981.69 In stock
RMB 3030.32 In stock
RMB 4653.78 In stock
RMB 7950.07 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Belinostat (PXD101) has been cited by 71 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Belinostat (PXD101, NSC726630, PX-105684) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.
Features Lead compound of Topotarget.
Targets
HDAC [1]
(Cell-free assay)
27 nM
In vitro

Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. Belinostat could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. [1] Belinostat inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. [2] The growth inhibitory activity of belinostat on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. Belinostat could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. Belinostat also shows enhanced tubulin acetylation in ovarian cancer cell lines. [3] A recent study shows that Belinostat activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MXPGeY5kfGmxbjDBd5NigQ>? NUGyN3pIOC57wrFOwG3DqA>? NUD4XHRXOjRiaB?= Ml\s[I94di2{ZXf1cIF1eyCWUzDwdo91\WmwIHzleoVteyCjZoTldkA3yqCqIHnuZ5Vj[XSrb36= NVy2SpZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlQ2QTRpPkG3NVI1PTl2PD;hQi=>
HCT116 NF:1ZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjueXM1QCCq MlHESWM2OD1yLkK4JO69VQ>? NYnBV|RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlQ2QTRpPkG3NVI1PTl2PD;hQi=>
Granta-519 M1TIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOEBp M1Lw[WlEPTB;NU[uN{DPxE1? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
Jeko-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWyOEBp MX;JR|UxRTBwMjFOwG0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
HBL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CxW|I1KGh? MnjVTWM2OD1yLkSg{txO MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
Panc-1  NELWWItCeG:ydH;zbZMhSXO|YYm= MnLCNVAxNzVyMD:xNFAxKG6P NVzlWGltPDhiaB?= NWjDclhGcW6mdXPld{Bld3OnIHTldIVv\GWwdDDhdI9xfG:|aYO= M2nIb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkixOlk5Lz5{Mk[4NVY6QDxxYU6=
AsPC-1 MXTBdI9xfG:|aYOgRZN{[Xl? NYLiO3ZWOTByL{WwNE8yODByIH7N M3vaXVQ5KGh? M3vlTIlv\HWlZYOg[I9{\SCmZYDlcoRmdnRiYYDvdJRwe2m| MmnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OEG2PVgoRjJ{NkixOlk5RC:jPh?=
T3M4 MV\BdI9xfG:|aYOgRZN{[Xl? NXPiOYRtOTByL{WwNE8yODByIH7N NWjTRZQ6PDhiaB?= NWD1[JVxcW6mdXPld{Bld3OnIHTldIVv\GWwdDDhdI9xfG:|aYO= M375VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkixOlk5Lz5{Mk[4NVY6QDxxYU6=
Panc-1  NXrPTIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rlV|AuQDByIH7N Mnv3OFghcA>? M{W1OolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NFTZOXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[4NVY6QCd-MkK2PFE3QTh:L3G+
AsPC-1 M2LiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjrd2cxNThyMDDuUS=> NIPHcW01QCCq NVvFOmRXcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NHzDcGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[4NVY6QCd-MkK2PFE3QTh:L3G+
T3M4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXGV4cxNThyMDDuUS=> MlrYOFghcA>? NIfTXoxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVPNU4w4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PFE3QThpPkKyOlgyPjl6PD;hQi=>
MiaPaCa2 MnvQSpVv[3Srb36gRZN{[Xl? NFjWfJcyNzFyIN88US=> MlnGNlQhcA>? Mki5bY5lfWOnczCg[5Jwf3SqIHHydoV{fGWmIHnuJGczN01? NFjHbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O|U3QTV:L3G+
AsPc1 NFPSbHdHfW6ldHnvckBCe3OjeR?= MWqxM|ExKM7:TR?= M4\nb|I1KGh? NHPFRWxqdmS3Y3XzJEBoem:5dHigZZJz\XO2ZXSgbY4hTzJxTR?= NVzkR4V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O|U3QTVpPkKzOFc2Pjl3PD;hQi=>
Panc0403 NVTNbVhjSXCxcITvd4l{KEG|c3H5 MlHXNUDPxE1? MlzGNlQhcA>? NHvubJFqdmS3Y3XzJIFxd3C2b4Ppdy=> NXHlXmRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O|U3QTVpPkKzOFc2Pjl3PD;hQi=>
Panc1005 MmHNRZBweHSxc3nzJGF{e2G7 NV;t[4pSOSEQvF2= M2j5dFI1KGh? NUHCUWhScW6mdXPld{BieG:ydH;zbZM> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NU[5OUc,OjN2N{W2PVU9N2F-
Panc0327 MoLBRZBweHSxc3nzJGF{e2G7 M4e0OFEh|ryP M{DIVFI1KGh? M{PuRYlv\HWlZYOgZZBweHSxc3nz MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ|NEe1Olk2RC:jPh?=
Panc0203 M{HMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH2OFghcA>? MU\FR|UxRTJ{LkKg{txO M{nWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEe1Olk2Lz5{M{S3OVY6PTxxYU6=
PL45 M2ixS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjJNI41QCCq MnvrSWM2OD1{MD64JO69VQ>? NGDhWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O|U3QTV:L3G+
Panc1005 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PSUlQ5KGh? NWHDb4lxTUN3ME2xMlEh|ryP NEC5e5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OVY6PSd-MkO0O|U3QTV:L3G+
Panc0403 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW0PEBp MWPFR|UxRTFwMTFOwG0> NVXvWHlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O|U3QTVpPkKzOFc2Pjl3PD;hQi=>
BxPc3 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXy0PEBp NXPEWpZRTUN3ME2xMlAh|ryP NVq1OGc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O|U3QTVpPkKzOFc2Pjl3PD;hQi=>
MiaPaCa2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjUV41pPDhiaB?= M2LvS2VEPTB;MD63JO69VQ>? M2jH[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEe1Olk2Lz5{M{S3OVY6PTxxYU6=
Panc0327 NIT3fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG1OFghcA>? NE\ZcolGSzVyPUCuOUDPxE1? NXPKPHlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O|U3QTVpPkKzOFc2Pjl3PD;hQi=>
AsPc1 NYjER5hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK0PEBp M3PkcmVEPTB;MD6zJO69VQ>? MnnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{W2PVUoRjJ|NEe1Olk2RC:jPh?=
PC9 NIXHSZVHfW6ldHnvckBCe3OjeR?= M1vBRVAvPS9zL{Kg{txO NVy0bok5PCCq MULEUXNQ NFizPIhqdmirYnn0d{B1cGVibHX2[Yx{KG:oIFHreEApeC2Da4SpJIFv\CCHR1\S MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
H1650 NF7VZ3FHfW6ldHnvckBCe3OjeR?= MmrONE42NzFxMjFOwG0> M33hRlQhcA>? MVrEUXNQ MmXNbY5pcWKrdIOgeIhmKGyndnXsd{Bw\iCDa4SgLJAuSWu2KTDhcoQhTUeIUh?= Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
H460 Mn\tSpVv[3Srb36gRZN{[Xl? Mlf6NE42NzFxMjFOwG0> MXy0JIg> MYrEUXNQ MoT5bY5pcWKrdIOgeIhmKGyndnXsd{Bw\iCDa4SgLJAuSWu2KTDhcoQhTUeIUh?= NInQSGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
PC9 M{LzZWZ2dmO2aX;uJGF{e2G7 MUm1NFDDqG6P NEXKXWwzPMLiaB?= NHXjO|NFVVOR MkPk[IVkemWjc3XzJGVITlJiZYjwdoV{e2mxbh?= NILkS2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
H1650 MVLGeY5kfGmxbjDBd5NigQ>? MU[1NFDDqG6P M{L2d|I1yqCq M1\lUmROW09? MXnk[YNz\WG|ZYOgSWdHWiCneIDy[ZN{cW:w M4PWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUG1O|UzLz5{M{WxOVc2OjxxYU6=
H460 NEft[nFHfW6ldHnvckBCe3OjeR?= NVnGZWZsPTBywrDuUS=> NHfiR4kzPMLiaB?= M3X3W2ROW09? Mlno[IVkemWjc3XzJGVITlJiZYjwdoV{e2mxbh?= MnHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
HCC4006 NHKzcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETQcYQ4OsLiaB?= NI\O[|dFVVOR M{n6[2lEPTB;MD60OkDPxE1? Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
HCC2935 NWr3dnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NuKhcA>? M2j2S2ROW09? MVTJR|UxRTBwOUeg{txO NFLFb2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
HCC827 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUW3NuKhcA>? NGr6[25FVVOR NInVRVJKSzVyPUCuNlkh|ryP M1zzVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUG1O|UzLz5{M{WxOVc2OjxxYU6=
HCC2279 NFvCVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3fVczyqCq MXLEUXNQ NV\PWmJzUUN3ME2wMlQh|ryP NX[4VIR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
PC9 M2LrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:0O|LDqGh? MnfISG1UVw>? MWPJR|UxRTBwMkmg{txO MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzNUe1Nkc,OjN3MUW3OVI9N2F-
H820 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmxO|LDqGh? M3LaUmROW09? MWnJR|UxRTBwNDFOwG0> MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
H1650 NWftSYVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu3NuKhcA>? M1vJe2ROW09? MUjJR|UxRTBwOEig{txO MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUW3OVIoRjJ|NUG1O|UzRC:jPh?=
H1975 NYDw[mFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fUfFczyqCq NH[wbXFFVVOR MojNTWM2OD1yLk[4JO69VQ>? NVPJdYtYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVU4PTJpPkKzOVE2PzV{PD;hQi=>
H520 NXnt[4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NuKhcA>? MXzEUXNQ MVHJR|UxRTBwN{Wg{txO NETYdFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
H1299 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXtUmQ4OsLiaB?= M2H4XmROW09? NE[4eXlKSzVyPUGuNkDPxE1? NGm2bFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
H460 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fidlczyqCq MWDEUXNQ MUPJR|UxRTBwOE[g{txO NFTHS2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
H1666 M3zJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vXU|czyqCq MoPxSG1UVw>? NYHobFFTUUN3ME6xNEDPxE1? NH;Tdmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxOVc2Oid-MkO1NVU4PTJ:L3G+
PANC-1 NGXpSpZHfW6ldHnvckBCe3OjeR?= NUHSdINtOTEEoN88US=> M2XjdFIwPCCq M3u4VGROW09? NWfGbm1qcW6lcnXhd4V{KGmwdILhZ4VtdHWuYYKgVm9UKGyndnXs NGDwVIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N|E6QCd-MkO3OFMyQTh:L3G+
PANC-1 MkG4R4VtdCCYaXHibYxqfHliQYPzZZk> NGfhSVUyNzFywrFOwG0> MorwOFghcA>? NHHlZYhFVVOR MorX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFPSdI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0N|E6QCd-MkO3OFMyQTh:L3G+
PANC-1 M3HHRWZ2dmO2aX;uJGF{e2G7 MWqxNOKh|ryP M{ftblIwPC94IHi= NHy2cIdFVVOR M4T1WYlv\HWlZYOgRW1RUyCjY4TpeoF1cW:w MoP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEOxPVgoRjJ|N{SzNVk5RC:jPh?=
HL-60  M2PURmZ2dmO2aX;uJGF{e2G7 MXewMlLDqM7:TR?= NHXFTXczPC92OD:3NkBp Mne4[Y5p[W6lZYOgVmEucW6mdXPl[EBoemGwdXzvZ5l1cWNiZHnm[oVz\W62aXH0bY9v NGH2TWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OFc{Oid-MkW4OlQ4OzJ:L3G+
NB4 MmnUSpVv[3Srb36gRZN{[Xl? NWPLO3VTOC5{wrFOwG0> Ml7ENlQwPDhxN{KgbC=> MUjlcohidmOnczDSRU1qdmS3Y3XkJIdz[W63bH;jfZRq[yCmaX\m[ZJmdnSrYYTpc44> M3PJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[0O|MzLz5{NUi2OFc{OjxxYU6=
HL-60  NXTHbIoxTnWwY4Tpc44hSXO|YYm= M1m0RVLDqM7:TR?= MlrQNlQwPDhiaB?= M{TyVIJtd2OtczDj[YxtKGO7Y3zlJIlvKFNicHjhd4U> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEezNkc,OjV6NkS3N|I9N2F-
NB4 MoW5SpVv[3Srb36gRZN{[Xl? NVzoNZIyOsLizszN Mli5NlQwPDhiaB?= MX;icI9kc3NiY3XscEBkgWOuZTDpckBUKHCqYYPl NU\BN5hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlQ4OzJpPkK1PFY1PzN{PD;hQi=>
HL-60  NHvOOHJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MonzNE4zNzMEoN88US=> MVOyOE81QC95MjDo MkLW[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEezNkc,OjV6NkS3N|I9N2F-
NB4 M1P4b2NmdGxiVnnhZoltcXS7IFHzd4F6 M2C5OVAvOi9{wrFOwG0> MU[yOE81QC95MjDo NWi5RWJE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkS3N|IoRjJ3OE[0O|MzRC:jPh?=
RAW264.7 M4r0NmFvfGlvaX7mcIFudWG2b4L5JIF{e2G7 NFzTcncyKGi{ NULIfGV4SW62aT3pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiSVy2JJBzd2S3Y4Tpc44heHKnLXnuZ5Vj[XSnZDDmc5IhOSCqcjDi[YZwemViTGDTJJN1cW23bHH0bY9vKG[xcjCyOEBpenNiYomgSWxKW0FibXX0bI9lNCCLQ{WwJF0hOC5yMECwOVkh|ryPLh?= NF7xW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxN|g4PSd-MkWxNVM5PzV:L3G+
HEK293 Mn3QSpVv[3Srb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKEiGQVO2JIlvKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuNFE2KM7:TT6= NXrTSlloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNFg2PjNpPkG4N|A5PTZ|PD;hQi=>
HEK293 NUG0So9STnWwY4Tpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKEiGQVOxJIlvKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuNFE5KM7:TT6= M4fwS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
HeLa Mom0SpVv[3Srb36gZZN{[Xl? NEW3bGc{OCCvaX7z M2C4O2lvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJ\UyjIHPlcIx{KG63Y3zlZZIh\Xi2cnHjeJMhcW6ldXLheIVlKG[xcjCzNEBucW6|IHL5JIZtfW:{ZYPj[Y51KGG|c3H5MEBKSzVyIE2gNE4xOjZ2IN88UU4> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzM{i3OUc,OjVzMUO4O|U9N2F-
HeLa MWnGeY5kfGmxbjDhd5NigQ>? NWPyc5RXUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEinTHGgZ4VtdHNidYPpcochTmy3b4Kg[IUhVHm|IHHzJJN2[nO2cnH0[UBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyO{DPxE1w Mn\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4M{m1N|coRjJ|NkO5OVM4RC:jPh?=
HeLa MkfPSpVv[3Srb36gZZN{[Xl? Mn\wTY5pcWKrdHnvckBw\iCKRFHDJIZzd21iaIXtZY4hUGWOYTDj[YxteyxiSVO1NEA:KDBwMEK4JO69VS5? NFjCNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O|U2PCd-MUiyOFc2PTR:L3G+
HEK293 MUfGeY5kfGmxbjDhd5NigQ>? MmrnTY5pcWKrdHnvckBw\iCKRFHDN{BqdiCKRVuyPVMh[2WubIOsJGlEPTBiPTCwMlA1PiEQvF2u M2rJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
MDA-MB-231 M1jNOWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoTsO|IhcHK| M1XOW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhemW|YYr1dolvKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkC2NkDPxE1w NWXu[pFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVY5ODRpPkK5OFU3QDB2PD;hQi=>
Jurkat M2LYSWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Mm\KOFghcHK| NWTOc3BDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODdizszNMi=> NUDjclN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|M5PzNpPkK5OVM{QDd|PD;hQi=>
A549 MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{S3UlczKGi{cx?= NETn[ZFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IILld4F7fXKrbjDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyIE2gNE4xPzdizszNMi=> NGLhPXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OlgxPCd-Mkm0OVY5ODR:L3G+
HeLa NXLvSYxySW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWf3eGdjPzJiaILz NHvQRmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IILld4F7fXKrbjDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyIE2gNE4xQDdizszNMi=> M3K0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW2PFA1Lz5{OUS1OlgxPDxxYU6=
MCF7 M4D5WmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUXRN3l{PzJiaILz M4nB[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nlicnXzZZp2emmwIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlA6PiEQvF2u NHjMSJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OlgxPCd-Mkm0OVY5ODR:L3G+
HEL MmW0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXi0PEBpenN? NUCwUFdNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDISWwh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w M37ySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUOzPFc{Lz5{OUWzN|g4OzxxYU6=
Huh7 MmrpRY51cX[rcnHsJIF{e2G7 M2LiZlMh\GG7cx?= MV7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3Yh\2Wwb4T5dIUhOWJiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{Bk\WyuczDh[pRmeiB|IHThfZMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNE4yOiEQvF2u MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUC3NFAoRjJ3NEmwO|AxRC:jPh?=
HCT116 NISxbZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXvnNlVuPDhiaILz MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6xN{DPxE1w NIPtSI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0OFQ5Pyd-MkezOFQ1QDd:L3G+
MOLT4 M3fOdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NFT6OZY1QCCqcoO= M37kXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVQh|ryPLh?= NEG1XG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN|g4Oyd-Mkm1N|M5PzN:L3G+
HCT116 NV\Kc|Y3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NYLNOYtQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFnDOVAhRSByLkG2JO69VS5? M1XpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkWwNlIyLz5{MU[1NFIzOTxxYU6=
HCT116 M{i2e2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NW\jdJpXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMtKEmFNUCgQUAxNjF4IN88UU4> MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5NEK0PVYoRjJzN{SyOFk3RC:jPh?=
SK-N-BE(2) M1jjdWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Ml3oOFghcHK| MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tRmUpOiliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzFizszNMi=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV|M{i3N{c,Ojl3M{O4O|M9N2F-
PC3 NUfs[WY{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYO0PEBpenN? NV;zdZpRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuN|kh|ryPLh?= M{LPcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S0OFg4Lz5{N{O0OFQ5PzxxYU6=
PC3 Mme3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NH35R4U6PiCqcoO= NYSxWVBwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPlcIx1cXSncjC5OkBie3OjeTygTWM2OCB;IECuOFUh|ryPLh?= NXvwXHZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2N|Q1OzBpPkKxOlM1PDNyPD;hQi=>
H1299 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYLwU4R6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDINVI6QSClZXzsd{whUUN3MDC9JFAvPDZizszNMi=> M3TrTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkWwNlIyLz5{MU[1NFIzOTxxYU6=
HeLa Mkn0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYG0PEBpenN? MmDLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZVzhJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkWxJO69VS5? MljTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O4O|MoRjJ7NUOzPFc{RC:jPh?=
HCT116 MmrzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M2Tsd|k3KGi{cx?= Mn33RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPlcIx1cXSncjC5OkBie3OjeTygTWM2OCB;IECuOkDPxE1w M2D3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
A2780 MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFXySFc6PiCqcoO= MmjFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDMke4NEBk\WyuczDh[pRmeiB7NjDodpMh[nliY3XscJRqfGW{IEm2JIF{e2G7LDDJR|UxKD1iMD62O{DPxE1w MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ|NESzNEc,OjF4M{S0N|A9N2F-
HuH7 MX;DfZRwfG:6aXPpeJkh[XO|YYm= MlWzN{Bl[Xm| NULteGJHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygeoli[mmuaYT5JIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKgPVYh[XO|YYmsJGNEPTBiPTCwMlY5KM7:TT6= NETwN4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NFcxOCd-MkW0PVA4ODB:L3G+
COLO205 MojsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{\4PFk3KGi{cx?= Mm\QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDj[YxtfGm2ZYKgPVYh[XO|YYmsJGlEPTBiPTCwMlch|ryPLh?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ|NESzNEc,OjF4M{S0N|A9N2F-
A549 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MmDVOFghcHK| MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwN{ig{txONg>? NYLZTnFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFQ1QDdpPkK3N|Q1PDh5PD;hQi=>
HL60 MmjKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUfqZ3IyPDhiaILz MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDFwMEmg{txONg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2NES4O{c,Ojd|NES0PFc9N2F-
K562 NUex[WpnSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWfUSYJnPDhiaILz MmnzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkGg{txONg>? NXKwZm1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|M5PzNpPkK5OVM{QDd|PD;hQi=>
PC3 M1;4SWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoHKOFghcHK| MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOS5|IN88UU4> M{\UTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUOzPFc{Lz5{OUWzN|g4OzxxYU6=
NFF NHHUc3lEgXSxdH;4bYNqfHliYYPzZZk> NVrSdnlVPzJiaILz M3TSfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5HTiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gNU41KM7:TT6= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ2MUGxNkc,Ojh{NEGxNVI9N2F-
HEK293 NH3HcI9EgXSxdH;4bYNqfHliYYPzZZk> MlS1OFghcHK| M{niTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB2ODDodpMh[nlicnXzZZp2emmwIHHzd4F6NCCLQ{WwJF0hOS52IN88UU4> NF;xRXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK0NVEyOid-MkiyOFEyOTJ:L3G+
NFF Mn3sR5l1d3SxeHnjbZR6KGG|c3H5 Mk[5O|IhcHK| MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEmFNUCgQUAyNjR{IN88UU4> M2H4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS1OFAzLz5|MEK0OVQxOjxxYU6=
HEK293 NXLKNIR5S3m2b4TvfIlkcXS7IHHzd4F6 M{myTlQ5KGi{cx?= NGjTeZVEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IILld4F7fXKrbjDkfYUh[mG|ZXSgZZN{[XluIFnDOVAhRSBzLkSyJO69VS5? NFrDdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK0OVQxOid-M{CyOFU1ODJ:L3G+
RAW264.7 NFPiVHBCdnSrLXnu[oxidW2jdH;yfUBie3OjeR?= NIDZbI8yKGi{ NF7Md4NCdnSrLXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCOUGOtd5RqdXWuYYTl[EBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBxemVvaX7jeYJifGWmIH\vdkAyKGi{IHLl[o9z\SCOUGOgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDHdolme3NicnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IEKuNkDPxE1w NX3r[4czRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVM5PzVpPkK1NVE{QDd3PD;hQi=>
RAW264.7 NIryVo5CdnSrLXnu[oxidW2jdH;yfUBie3OjeR?= M2rSOlEhcHJ? MkC5RY51cS2rbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hVFCVLYP0bY12dGG2ZXSgcY92e2ViUlHXNlY1NjdiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhXE6IYXzwbIEheHKxZIXjeIlwdiCycnWtbY5kfWKjdHXkJIZweiBzIHjyJIJm\m:{ZTDMVHMhe3SrbYXsZZRqd25iZn;yJFI1KGi{czDifUBGVEmVQTDt[ZRpd2RuIFnDOVAhRSB2Lkeg{txONg>? NIHVeII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxN|g4PSd-MkWxNVM5PzV:L3G+
RAW264.7 M{DWXWFvfGlvaX7mcIFudWG2b4L5JIF{e2G7 NIX3Vo4yKGi{ MX;BcpRqNWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBNWFNvc4TpcZVt[XSnZDDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBRT0V{IIDyc4R2[3Srb36gdJJmNWmwY4XiZZRm\CCob4KgNUBpeiCkZX\vdoUhVFCVIIP0bY12dGG2aX;uJIZweiB{NDDodpMh[nliZX76fY1mKGmvbYXuc4F{e2G7IH3leIhw\CxiSVO1NEA:KDhwMkig{txONg>? NH;keHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxN|g4PSd-MkWxNVM5PzV:L3G+
Huh-luc/neo7 MVzGeY5kfGmxbjDhd5NigQ>? NILNOIgyKHWP M1HlTFEhfG9iMzDodpM> MmDMTY5pcWKrdHnvckBw\iCKRFHDJINt[XO|IEGgbY4hcHWvYX6gTJVpNWy3Yz;u[Y84KGOnbHzzJIF{e2W|c3XkJIF{KGirc4TvcoUhUDNiYXPleJlt[XSrb36gZZQhOSC3TTDh[pRmeiBzIITvJFMhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm|aYO= M1vK[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3NFE4Lz5{NUmzO|AyPzxxYU6=
PC3 MnfxSpVv[3Srb36gZZN{[Xl? MmPDNE4{KHWP MWG0PEBpenN? MVPJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHHtc5VvfCCxZjDhZ4V1gWyjdHXkJIhqe3SxbnWgTFMh[XRiMD6zJJVOKGGodHXyJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NWnlPFh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFQ1QDdpPkK3N|Q1PDh5PD;hQi=>
HCT116 NYnCW3NKTnWwY4Tpc44h[XO|YYm= MoTCNE4{KHWP M2HzTlQ5KGi{cx?= NF7MNmRKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGvb4XueEBw\iCjY3X0fYxifGWmIHjpd5RwdmViSEOgZZQhOC5|IIXNJIFnfGW{IES4JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> Mn7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NES0PFcoRjJ5M{S0OFg4RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK ; 

PubMed: 28397399     


Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (0.1, 0.2, 0.3, 1, 3 μm). Immunoblotting was performed to evaluate the changes in phosphorylated protein levels of the targets identified in 1D (ERK1/2, p38, B‐Raf, MEK1/2) as well as PARP. β‐Actin shown as loading control. 

SOS1 / SOS2; 

PubMed: 28397399     


(A) Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (PXD101) (0.1, 0.2, 0.3, 1, 3 μm) to evaluate the changes in SOS1 and SOS2. 

p21 / p27 ; 

PubMed: 23982416     


(A and B) The cell lines shown were treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h. Whole cell extracts were generated and subjected to western blotting with antibodies against p21, p27, hsp90, α-tubulin, or GAPDH. PXD101-resistant cell lines are shown in (A, left) while PXD101-sensitive cell lines are shown in (B, right). 

Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin; 

PubMed: 24155971     


PXD101 induced acetylation of histone H3 and histone H4 in a dose-dependent manner. PXD101 also increased acetylation of tubulin in BHP7-13, WRO82-1 and 8505C.

p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 ; 

PubMed: 24155971     


increasing doses of PXD101 enhanced degradation of KU70, KU80 and RAD51, and enhanced expression of p-H2AX (Ser139), RAD52 and ERCC1 in BHP7-13, WRO82-1 and 8505C.

28397399 23982416 24155971
Growth inhibition assay
IC50; 

PubMed: 28397399     


Lung SCC cell lines and normal lung fibroblast cell lines were treated with belinostat (PXD101) for 72 h, and cell viability was determined with CellTiter assay. Data are represented as mean IC50 ± SD (n = 3).

Cell viability; 

PubMed: 24155971     


Dose-response curves were obtained on day 4 from cells treated with a series of six 1:1 dilutions of PXD101. 

28397399 24155971
In vivo Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. [1] Belinostat also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. [2] Belinostat monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of Belinostat (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. [3] Combining with bortezomib, Belinostat results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft. [5]

Protocol

Kinase Assay:[1]
- Collapse

Histone Deacetylase Activity:

Subconfluent cultures are harvested and washed twice in ice cold PBS and pelleted by centrifugation at 200 × g for 5 min. The cell pellet is resuspended in two volumes of lysis buffer [60 mM Tris buffer (pH 7.4) containing 30% glycerol and 450 mM NaCl] and lysed by three freeze (dry ice) thaw (30 °C water bath) cycles. Cell debris is removed by centrifugation at 1.2 × 104 g for 5 min, and the supernatant is stored at −80 °C. Histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRK corresponding to the 20 NH2-terminal residues) is acetylated by a recombinant protein containing the hypoxanthine-aminopterin-thymidine domain of p300, using [3H]acetyl CoA as a source of acetate. H4 peptide (100 μg) is mixed with hypoxanthine-aminopterin-thymidine buffer (50 mM Tris HCl pH 8.0, 5% glycerol, 50 mM KCl, and 0.1 mM EDTA), 1 mM DTT, 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1 × complete protease inhibitors, 50 μL of purified p300, and 1.85 m [3H]acetyl CoA (4.50Ci/mmol) in a final volume of 300 μL and incubated at 30 °C for 45 min. The p300 protein is removed by incubation with 20 μL of 50% Ni-agaroase beads for 1 hour at 4 °C and centrifugation. The supernatant is applied to a 2 mL Sephadex G15 column, and the flow through is collected. One milliliter of distilled H2O is gently applied, and three drop fractions are collected; this is repeated until 4–5 mL of distilled H2O has been added, and ∼40 fractions are collected. Three microliters of each fraction are diluted in 2 mL of scintillation fluid and counted in a scintillation counter to identify the fractions containing the labeled peptide. These fractions are pooled, and 1 μL of the combined sample is measured to assess the radioactivity in every peptide batch (3-7×103 cpm/μL). For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of belinostat. The reaction is started by the addition of 2 μL of [3H] labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH2-terminal residues). Samples are incubated at 37 °C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [3H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 1.2× 104 g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted.
Cell Research:[1]
- Collapse
  • Cell lines: A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852
  • Concentrations: 0.016 - 10 μM
  • Incubation Time: 24 hours
  • Method: Tumor cell lines are seeded in 5 mL of medium at a density of 8 × 104 cells/25 cm2 flask and incubated for 48 hours. Cells are exposed to Belinostat (0.016 to 10 μM) for 24 hours. The medium is removed, and 1 mL of trypsin/EDTA is added to each flask. Once the cells have detached, 1 mL of medium is added, the cells are resuspended, and those from the control untreated flask are counted. Cells are diluted and plated into 6-cm Petri dishes (three per flask) at a density of 0.5-2× 103 cells/dish depending on the cell line. Cells from the drug-treated flasks are diluted and plated as for the control flasks. Dishes are incubated for 10–15 days at 37 °C. Cells are washed with PBS, fixed in methanol, and stained with crystal violet, and colonies that contained ≥50 cells counted. Sensitivity is expressed as the IC50 defined as the concentration of belinostat required to reduce the number of colonies to 50% of that of the control untreated cells.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A2780, A2780/cp70 and HCT116 cells are injected s.c. into the right flank of CD1 nu/nu mice.
  • Dosages: ≤40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 64 mg/mL (201.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 318.35
Formula

C15H14N2O4S

CAS No. 414864-00-9
Storage powder
in solvent
Synonyms NSC726630, PX-105684
Smiles C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04315233 Recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma October 29 2020 Phase 1
NCT03772925 Recruiting Drug: Belinostat|Drug: Pevonedistat Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome National Cancer Institute (NCI) February 28 2019 Phase 1
NCT02680795 Recruiting Drug: Belinostat IV Solid Tumors|Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1
NCT02679131 Terminated Drug: Belinostat Relapsed/Refractory Solid Tumors/Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please give some suggestions for the use of Belinostat in vivo (i.p. injection)?

  • Answer:

    For I.P. injection, S1085 Belinostat (PXD101) can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Belinostat (PXD101) | Belinostat (PXD101) supplier | purchase Belinostat (PXD101) | Belinostat (PXD101) cost | Belinostat (PXD101) manufacturer | order Belinostat (PXD101) | Belinostat (PXD101) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID